FIA
BLPH

FNY Investment Advisers’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

FNY Investment Advisers’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-453
Closed -$3K – 1190
2019
Q3 		$3K Hold
453
– – ﹤0.01% 711
2019
Q2 		$4K Buy
+453
New +$4.34K ﹤0.01% 764

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

FNY Investment Advisers's BLPH Position: Q4 2019 in Review

FNY Investment Advisers sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2019, closing a stake of 453 shares — an estimated $3K sold.

FNY Investment Advisers first reported a position in BLPH in Q2 2019 and held it in 2 quarters. The position peaked at $4K in Q2 2019. 19 funds tracked by Wall St. Rank hold BLPH as of Q4 2019.

  • FNY Investment Advisers reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 453 Bellerophon Therapeutics, Inc. shares in Q4 2019, an estimated $3K.
  • FNY Investment Advisers first reported a position in Bellerophon Therapeutics, Inc. in Q2 2019 and held it in 2 quarters.
  • FNY Investment Advisers's Bellerophon Therapeutics, Inc. position peaked at $4K in Q2 2019.
  • 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2019.

Based on FNY Investment Advisers's 13F filing for Q4 2019, filed 10 Jan 2020.